Pacific Biosciences Of California Inc Revenue Growth Rates (PACB), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Pacific Biosciences Of California Inc   (NASDAQ: PACB)
 

PACB's Revenue Growth by Quarter and Year

Pacific Biosciences Of California Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/PACB/growth
https://api.csimarket.com/api/v1/companies/PACB/fundamentals
https://api.csimarket.com/api/v1/companies/PACB/fundamentals?mode=as_of&as_of=YYYY-MM-DD
Programmatic access for models, analytics, and integration workflows.
Explore the Financial Data API
Financial API Point-in-Time Financial Fundamentals API API Server API Docs API Discovery
Connect Your AI Assistant
How to Connect Your AI Assistant to CSIMarket MCP MCP Server
Access this full dataset via API
Free sample Full docs All endpoints
PACB Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 40.56
2nd Quarter June 39.01
1st Quarter March 36.84
FY 116.41

PACBs Annual Revenue
Pacific Biosciences Of California Inc 's Revenue in the fiscal year 2025 $ 159.78 millions
Pacific Biosciences Of California Inc 's Revenue in the fiscal year 2024 $ 153.28 millions
Pacific Biosciences Of California Inc 's Revenue in the fiscal year 2023 $ 199.78 millions
Pacific Biosciences Of California Inc 's Revenue in the fiscal year 2022 $ 128.30 millions
Pacific Biosciences Of California Inc 's Revenue in the fiscal year 2021 $ 130.51 millions




PACB Revenue third quarter 2026 Y/Y Growth Comment
Pacific Biosciences Of California Inc reported Revenue growth of 7.03% year on year in the third quarter 2026, to $ 40.56 millions, this is lower than Pacific Biosciences Of California Inc 's recent average Revenue surge of 184.36%.

Looking into third quarter 2026 results within Laboratory Analytical Instruments industry 16 other companies have achieved higher Revenue growth. While Pacific Biosciences Of California Inc ' s Revenue increase of 7.03% ranks overall at the positon no. 2937 in the third quarter 2026.


PACB Revenue ( Y/Y Growth %) 2026
 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 7.03 %
2nd Quarter June -1.69 %
1st Quarter March 0.57 %
FY   -

Financial Statements
Pacific Biosciences Of California Inc 's third quarter 2026 Revenue $ 40.56 millions PACB's Income Statement
Pacific Biosciences Of California Inc 's third quarter 2025 Revenue $ 37.90 millions Quarterly PACB's Income Statement


PACB Revenue (Quarter on Quarter Growth %)

 2026
 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 3.98 %
2nd Quarter June 5.89 %
1st Quarter March -19.16 %
FY (Year on Year)   -


Back to PACB Growth rate Comparisons >> Back to PACB Growth rate Comparisons >>


Revenue third quarter 2026 Y/Y Growth Company Ranking
Within: No.
Laboratory Analytical Instruments Industry #17
Healthcare Sector #410
Overall #2937

Revenue Y/Y Growth Statistics
High Average Low
4681.36 % 184.36 % -73.61 %
(Jun 30 2012)   (Mar 31 2013)
Revenue third quarter 2026 Y/Y Growth Company Ranking
Within: No.
Laboratory Analytical Instruments Industry #17
Healthcare Sector #410
Overall #2937
Revenue Y/Y Growth Statistics
High Average Low
4681.36 % 184.36 % -73.61 %
(Jun 30 2012)   (Mar 31 2013)

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Pacific Biosciences Of California Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
3837.04 % 67.6 % -65.02 %
(Jun 30 2011)  


PACB's III. Quarter Q/Q Revenue Comment
Pacific Biosciences Of California Inc achieved in the III. Quarter 2026 below company average Revenue growth of 3.98% quarter on quarter, to $ 40.56 millions.

III. Quarter 2026 Revenue Q/Q growth were paradoxical, although lower than the regular, yet it demonstrates absolute recovery measured to the -4.49% in the III. Quarter a year ago.

Within Laboratory Analytical Instruments industry 2 other companies have achieved higher Revenue quarter on quarter growth. While Pacific Biosciences Of California Inc 's Revenue growth quarter on quarter, overall rank is 1085.


Revenue Q/Q Growth Company Ranking
Within: No.
Laboratory Analytical Instruments Industry #3
Healthcare Sector #159
Overall #1085
Revenue Q/Q Growth Company Ranking
Within: No.
Laboratory Analytical Instruments Industry #3
Healthcare Sector #159
Overall #1085
Revenue Q/Q Growth Statistics
High Average Low
3837.04 % 67.6 % -65.02 %
(Jun 30 2011)  


PACB's III. Quarter Q/Q Revenue Comment
Pacific Biosciences Of California Inc achieved in the III. Quarter 2026 below company average Revenue growth of 3.98% quarter on quarter, to $ 40.56 millions.

III. Quarter 2026 Revenue Q/Q growth were paradoxical, although lower than the regular, yet it demonstrates absolute recovery measured to the -4.49% in the III. Quarter a year ago.

Within Laboratory Analytical Instruments industry 2 other companies have achieved higher Revenue quarter on quarter growth. While Pacific Biosciences Of California Inc 's Revenue growth quarter on quarter, overall rank is 1085.


Pacific Biosciences Of California Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Jun 30 2026)		 12 Months Ending (Mar 31 2026) 12 Months Ending (Dec 31 2025) 12 Months Ending (Sep 30 2025) 12 Months Ending (Jun 30 2025)
Cumulative Revenue 12 Months Ending $ 159.32
Y / Y Revenue Growth (TTM) 2.54 %
Year on Year Revenue Growth Overall Ranking # 3379
Seqeuential Revenue Change (TTM) -0.42 %
Seq. Revenue Growth (TTM) Overall Ranking # 2359


Cumulative Revenue growth Comment
With the quarterly Revenue reported in the Jun 30 2026 period, Pacific Biosciences Of California Inc 's cumulative twelve months Revenue were $ 159 millions, company would post below average annual Revenue growth of -0.42% year on year, if the fiscal year would end at Jun 30 2026.
A slow-down in the Pacific Biosciences Of California Inc 's Revenue growth from the 39.01% growth in Mar 31 2026.

In the Healthcare sector 450 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 2757 to 3379.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Laboratory Analytical Instruments Industry # 12
Healthcare Sector # 451
Overall # 3379

Revenue TTM Y/Y Growth Statistics
High Average Low
242.94 %
 21.22 %
-50.67 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 12
Sector # 339
S&P 500 # 2359
Cumulative Revenue growth Comment
With the quarterly Revenue reported in the Jun 30 2026 period, Pacific Biosciences Of California Inc 's cumulative twelve months Revenue were $ 159 millions, company would post below average annual Revenue growth of -50.67% year on year, if the fiscal year would end at Jun 30 2026.
A slow-down in the Pacific Biosciences Of California Inc 's Revenue growth from the 39.01% growth in Mar 31 2026.

In the Healthcare sector 450 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 2757 to 3379.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Laboratory Analytical Instruments Industry # 12
Healthcare Sector # 451
Overall # 3379

Revenue TTM Y/Y Growth Statistics
High Average Low
242.94 %
21.22 %
-50.67 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 12
Sector # 339
S&P 500 # 2359




Other Revenue Growth
Laboratory Analytical Instruments Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
PACB's Revenue Growth Ratio versus Laboratory Analytical Instruments Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue growth for the quarter ending Sep 30 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Sep 30 2026
Viemed Healthcare Inc 12.18%$ 12.180 millions
Ufp Technologies Inc 12.15%$ 12.154 millions
Innovage Holding Corp 12.14%$ 12.135 millions
Vertex Pharmaceuticals Inc11.85%$ 11.845 millions
Sanara Medtech Inc 11.67%$ 11.668 millions
Lemaitre Vascular Inc 11.51%$ 11.508 millions
Pacs Group Inc 11.45%$ 11.454 millions
Ocugen Inc 11.36%$ 11.358 millions
Dexcom Inc 11.26%$ 11.263 millions
Elanco Animal Health Incorporated11.26%$ 11.258 millions
Koru Medical Systems Inc 11.19%$ 11.194 millions
Elite Pharmaceuticals Inc 11.11%$ 11.113 millions
Pro dex Inc 10.96%$ 10.955 millions
Nrc Health10.95%$ 10.954 millions
Anika Therapeutics Inc 10.91%$ 10.912 millions
Harvard Bioscience Inc 10.86%$ 10.864 millions
Repligen Corp10.86%$ 10.863 millions
Warby Parker Inc 10.77%$ 10.767 millions
Cerus Corporation10.69%$ 10.690 millions
Biogen Inc 10.63%$ 10.628 millions
Chemed Corporation10.57%$ 10.568 millions
Edwards Lifesciences Corporation10.47%$ 10.471 millions
Biodesix Inc 10.44%$ 10.442 millions
Medline Inc 10.41%$ 10.415 millions
Jazz Pharmaceuticals Plc10.38%$ 10.380 millions
Abbvie Inc 10.32%$ 10.319 millions
Livanova Plc10.17%$ 10.170 millions
Kura Oncology Inc 10.07%$ 10.067 millions
Amneal Pharmaceuticals Inc 10.04%$ 10.040 millions
Quest Diagnostics Inc9.98%$ 9.979 millions


About Pacific Biosciences Of California Inc Revenue Growth Rates (PACB), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Pacific Biosciences Of California Inc (CIK 1299130).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001299130-26-000138
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Pacific Biosciences Of California Inc’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.